paxlovid
paxlovid: sourced relationships with 1 company · 2 clinical trials tracked · 1 FDA decision.
paxlovid evidence translation
What we can confirm
1 FDA record · 2 tracked trials
What it means
What to watch
Prepared research question
How could paxlovid → PFE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| PFIZER INC (PFE) Reported 2023-05-25 · Current development: unknownSource | Approved |
| PFIZER INC (PFE) Reported 2023-05-25 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (2)
A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir and Standard of Care in Non-hospitalized Symptomatic Adult Participants With Mild to Moderate COVID-19
Primary endpoint: Safety based on adverse events incidence
Randomised Evaluation of COVID-19 Therapy
Primary endpoint: Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)
Frequently asked questions
Which companies have sourced relationships with paxlovid?
paxlovid has dated SEC/FDA relationship records for PFIZER INC.
How many clinical trials involve paxlovid?
BioSniper tracks 2 clinical trials involving paxlovid.
What is paxlovid's latest FDA decision?
The most recent tracked FDA decision for paxlovid is Approval, dated May 25, 2023.